• Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.

      Rudin, C; Hann, C; Garon, E; Ribeiro de Oliveira, M; Bonomi, P; Camidge, D; Chu, Q; Giaccone, G; Khaira, D; Ramalingam, S; et al. (2012-06-01)
      Bcl-2 is a critical regulator of apoptosis that is overexpressed in the majority of small cell lung cancers (SCLC). Nativoclax (ABT-263) is a potent and selective inhibitor of Bcl-2 and Bcl-x(L). The primary objectives of this phase IIa study included safety at the recommended phase II dose and preliminary, exploratory efficacy assessment in patients with recurrent and progressive SCLC after at least one prior therapy.